Cargando…

Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues

Detalles Bibliográficos
Autor principal:	Simon, D.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2009
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789934/ https://www.ncbi.nlm.nih.gov/pubmed/19859691 http://dx.doi.org/10.1007/s00125-009-1572-8

Ejemplares similares

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus
por: Eledrisi, Mohsen, et al.
Publicado: (2018)

Social Data: Biases, Methodological Pitfalls, and Ethical Boundaries
por: Olteanu, Alexandra, et al.
Publicado: (2019)

Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
por: Perfetti, Riccardo
Publicado: (2018)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
por: Barnett, Anthony H
Publicado: (2006)

Similar risk of exercise‐related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross‐over trial
por: Heise, T., et al.
Publicado: (2015)

A possible link between insulin glargine and malignancy: the facts
por: Mollentze, WF
Publicado: (2009)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis
por: Tang, Xulei, et al.
Publicado: (2012)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

The highest (3600 IU) reported overdose of insulin glargine ever and management
por: Karatas, Fatih, et al.
Publicado: (2015)

Combined randomised controlled trial experience of malignancies in studies using insulin glargine
por: Home, P. D., et al.
Publicado: (2009)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
por: Tien, Kai‐Jen, et al.
Publicado: (2019)

A Salutary Tale—Glargine insulin and cancer risk
por: Boyle, Peter
Publicado: (2009)

Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials
por: Vora, J., et al.
Publicado: (2016)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Yamabe, Mizuho
Publicado: (2019)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020)

Comment on “a comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes”
por: Freemantle, Nick, et al.
Publicado: (2019)

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
por: Wang, Zhihui, et al.
Publicado: (2010)

The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
por: Hilgenfeld, Rolf, et al.
Publicado: (2014)

Insulin glargine in pediatric patients with type 1 diabetes in Japan
por: Urakami, Tatsuhiko, et al.
Publicado: (2014)

Glargine versus regular insulin protocol in feline diabetic ketoacidosis
por: Zeugswetter, Florian K., et al.
Publicado: (2021)

Citation Frequency and Ethical Issue
por: Ebrahim, Nader Ale
Publicado: (2014)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
por: Wolffenbuttel, B. H. R., et al.
Publicado: (2016)

Methodological Issues in Treatment Adherence Studies
por: Upadhyay, Ravi Prakash, et al.
Publicado: (2012)

Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial
por: Pieber, Thomas R., et al.
Publicado: (2021)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020)

Treatment compliance and noncompliance in psychosis: Methodological issues
por: Pinto, Ekta Franscina, et al.
Publicado: (2017)

Cohort Study of Insulin Glargine and Risk of Breast, Prostate, and Colorectal Cancer Among Patients With Diabetes
por: Habel, Laurel A., et al.
Publicado: (2013)

Improvement of glycemic control without severe hypoglycemia in a type 1 diabetes patient undergoing hemodialysis after a change from insulin glargine to insulin degludec
por: Takahashi, Nobuyuki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fdfa3rjqo979i16e62n5dlqehg